Evidence map›Paper›PMID 33966476›Full record

ArticleJournal of investigative medicine high impact case reports

A Rare Case of Double Antibody-Positive Rapidly Progressive Glomerulonephritis: A Therapeutic Challenge.

Stephen Bell, Natalia Lattanzio, Qassem Abdelal, Yeshanew Teklie, Talal Alkayali, Wilhelmine Wiese-Rometsch, Ashok Sastry

Open access · goldAbstract readCase Reports
In one paragraph

Article in Journal of investigative medicine high impact case reports. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.7field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. A Rare Case of ANCA-negative Rapidly Progressive Glomerulonephritis: A Case Report.Journal of community hospital internal medicine perspectives · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Stephen BellFlorida State University, Sarasota, FL, USA.ORCID 0000-0003-3220-9047
Natalia LattanzioFlorida State University, Sarasota, FL, USA.
Qassem AbdelalFlorida State University, Sarasota, FL, USA.
Yeshanew TeklieFlorida State University, Sarasota, FL, USA.
Talal AlkayaliFlorida State University, Sarasota, FL, USA.
Wilhelmine Wiese-RometschFlorida State University, Sarasota, FL, USA.
Ashok SastryFlorida State University, Sarasota, FL, USA.
Florida State University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Crescentic glomerulonephritis, also known as rapidly progressive glomerulonephritis, is a syndrome characterized by progressive and rapid deterioration of renal function over the course of weeks to months. Oliguria, hematuria, azotemia, and hypertension are characteristic features of this condition. Crescentic glomerulonephritis is further classified according to the staining pattern on immunofluorescence. In rare instances, a mixed pattern of injury is encountered as in the case of double antibody-positive rapidly progressive glomerulonephritis (RPGN). This case illustrates the challenge in treatment of double antibody-positive RPGN in an elderly female with no previous renal disease. The patient was found to be positive for anti-GBM antibody and MPO-ANCA. Treatment was initially targeted against MPO-ANCA as the biopsy was most consistent with this process; however, the patient failed to respond to treatment and was subsequently transitioned to oral cyclophosphamide directed against anti-GBM disease. In cases of doubly antibody-positive RPGN with anti-GBM disease and ANCA-associated vasculitis, initial treatment should focus on inducing remission of anti-GBM disease as double antibody-positive disease often presents with the aggressive morbidity and mortality seen in anti-GBM disease, and the chronic risk of relapse seen in ANCA-mediated vasculitis.

Indexed as

GlomerulonephritisAgedAntibodies, Antineutrophil CytoplasmicBiopsyCyclophosphamideFemaleHumansImmunosuppressive AgentsAntibodies, Antineutrophil CytoplasmicCyclophosphamideImmunosuppressive AgentsANCA-associated vasculitisanti-glomerular basement membrane diseasecrescentic glomerulonephritis

Identifiers

PMID33966476
PMCPMC8114315
OpenAlexW3161468848

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.